Like enzymes and coenzymes, monitoring devices and pharmacists may achieve more together than either can alone.
Publication|Articles|October 24, 2025
- Fall 2025
- Volume 19
- Issue 2
Fall 2025 Quiz: Test Your Pharmacy Knowledge!
This quiz was created in collaboration with PTCE™.
Advertisement
A patient comes to the pharmacy and picks up a new prescription for atorvastatin 20 mg once daily. The patient asks you if there is anything to keep in mind while on this medication. Which is the best response?
Articles in this issue
6 months ago
Spring 2026 Quiz: Test Your Pharmacy Knowledge!about 1 year ago
A Silent Struggle Behind the White Coatabout 1 year ago
From Stigma to Breakthrough: Psychedelic Medicineabout 1 year ago
The Juggling Act: Navigating Pharmacy School and Parentingabout 1 year ago
UConn’s Medical Writing Certificate Program: It’s Just "Write"Advertisement
Related to this article
Every responsibility described in this issue depends on a pharmacy workforce with enough time and support to carry it.
Payer requirements, prescriber habits, and operational realities ultimately determine which ICI patients receive.
Christie Ballantyne, MD, explains how the CORALreef Extension study adds safety exposure and shows LDL-C lowering with oral enlicitide is sustained over time.
At SITC 2026, 10 of 15 patients with advanced melanoma responded to investigational amsokigene autoleucel at the recommended phase 2 dose, with 5 still in response 12 months after infusion.
The glucagon/GLP-1 dual agonist did not raise major adverse cardiovascular event risk in adults with obesity, but GI-related discontinuations were high.
Post hoc AHA 2026 data show the oral GLP-1 receptor agonist lowered systolic blood pressure across hypertension stages, partly beyond weight loss.
The evidence for GLP-1 receptor agonists keeps growing, while access for low-income patients keeps narrowing.
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Requires Class-Wide GLP-1 RA Labeling Changes for Potential NAION Risk
2
Understanding Kratom: Pharmacology, Safety, and Regulation
3
Survodutide Shows Cardiovascular Safety in SYNCHRONIZE-CVOT
4
Oral PCSK9 Inhibitor Enlicitide Sustains LDL-C Reductions
5